Acquirer(s)
- Australian Clinical Labs Limited
Target(s)
- Healius Limited
Summary
On 20 March 2023, Australian Clinical Labs Limited (ACL) announced that it was seeking to acquire Healius Limited (Healius) by way of an off-market takeover offer to acquire all the fully paid ordinary shares in Healius.
ACL and Healius provide human pathology services to out-patients, in-patients (at public and private hospitals), and commercial and government customers, as well as veterinary pathology services. Healius also provides diagnostic imaging services.
A Public Competition Assessment will be published in due course.
Draft undertakings
Market inquiries
| Document title | Date | |
|---|---|---|
| ACL Healius - market inquiries letter |
Statement of issues
| Document title | Date | |
|---|---|---|
| ACL Healius - Statement of Issues |
Timeline
| Date | Event |
|---|---|
ACCC commenced review under the Merger Process Guidelines. |
|
Closing date for submissions. |
|
Timeline suspended. Former provisional date for announcement of ACCC’s findings (22 June) delayed at ACL’s request. ACCC will announce a revised provisional decision date in due course. |
|
ACCC received further information from ACL. Timeline recommenced. |
|
ACCC published a Statement of Issues outlining preliminary competition concerns. |
|
Closing date for submissions relating to Statement of Issues. |
|
Timeline suspended pending receipt of further information. Former proposed decision date for announcement of ACCC's findings (12 October 2023) is delayed. |
|
ACCC commenced market consultation on proposed s87B undertaking. |
|
Closing date for submissions relating to the proposed s87B undertaking. |
|
ACCC received further information. Timeline recommenced. |
|
ACCC announced it would oppose the proposed acquisition. |